Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 816-824

  Else, L J ^a,c   Douglas, M ^b   Dickinson, L ^c   Back, D J ^a   Khoo, S H ^a   Taylor, G P ^b,d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PUERPERIUM; SECOND TRIMESTER PREGNANCY; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; THIRD TRIMESTER PREGNANCY; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CAPSULES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GELATIN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; TABLETS; VIRAL LOAD; YOUNG ADULT;

EID: 84856067531     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05186-11     Document Type: Article

References (39)

1. Aweeka FT, et al. 2010. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 11:232-238.
2. Bertz R, Foit C, Burt D. 2002. Assessment of the effect of nevirapine on the pharmacokinetics of lopinavir/ritonavir (Kaletra®) after multiple dosing in HIV-infected adults, abstr TuPeB4565.Abstr. XIV Int. AIDS Conf.
3. Best BM, et al. 2010. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J. Acquir. Immune Defic. Syndr. 54:381-388.
4. Boer K, et al. 2007. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG 114:148-155. (Pubitemid 46089443)
5. Boffito M, et al. 2003. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retroviruses 19:825-835. (Pubitemid 37215138)
6. Boffito M, et al. 2004. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther. Drug Monit. 26:35-39. (Pubitemid 38140908)
7. Boffito M, et al. 2008. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir. Ther. 13:901-907.
8. Breilh D, et al. 2004. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 18:1305-1310. (Pubitemid 38822709)
9. Chappuy H, et al. 2004. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48:4332-4336. (Pubitemid 39434895)
10. Dickinson L, Khoo S, Back D. 2008. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr. Opin. HIV AIDS 3:296-305. (Pubitemid 351521014)
11. Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. 2003. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J. Acquir. Immune Defic. Syndr. 32:287-291. (Pubitemid 36331700)
12. Dumond JB, et al. 2007. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 21:1899-1907. (Pubitemid 47329766)
13. Else L, et al. 2010. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878:1455-1465.
14. Fayet A, et al. 2009. Free and total pharmacokinetics of lopinavir (LPV), atazanavir (ATV) and nevirapine (NVP) during the course of pregnancy, in the umbilical cord and at post-partum, abstr P57. Abstr. 10th. Int. Workshop Clin. Pharmacol. HIV Ther.
15. Gauthier J, et al. 2009. Therapeutic drug monitoring of lopinavir/ritonavir (tablet formulation) in pregnancy, abstr P49. Abstr. 10th. Int. Workshop Clin. Pharmacol. HIV Ther.
16. Israili ZH, Dayton PG. 2001. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33:161-235. (Pubitemid 32703255)
17. Kappelhoff BS, et al. 2004. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. 43:845-853. (Pubitemid 39447031)
18. Khuong-Josses MA, Azerad D, Boussairi A, Ekoukou D. 2007. Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women. HIV Clin. Trials 8:254-255. (Pubitemid 47327463)
19. Klein CE, et al. 2007. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J. Acquir. Immune Defic. Syndr. 44:401-410. (Pubitemid 46555374)
20. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. 2007. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 21:607-615.
21. Lambert J, et al. 2011. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med. 12:166-173.
22. La Porte CJL, et al. 2006. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev. Antiviral Ther. 3:4-14.
23. Manavi K, McDonald A, Al-Sharqui A. 2007. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 21:643-645.
24. Martin F, Taylor GP. 2007. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J. Infect. Dis. 196:558-561. (Pubitemid 47206102)
25. Masquelier B, et al. 2002. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 46:2926-2932.
26. Mirochnick M, et al. 2008. Lopinavir exposure with an increased dose during pregnancy. J. Acquir. Immune Defic. Syndr. 49:485-491.
27. Notarianni LJ. 1990. Plasma protein binding of drugs in pregnancy and in neonates. Clin. Pharmacokinet. 18:20-36. (Pubitemid 20040336)
28. Ofotokun I, Chuck SK, Hitti JE. 2007. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend. Med. 4:106-119. (Pubitemid 47248489)
29. Perinatal HIV Guidelines Working Group. 24 May 2010, posting date. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. U.S. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/contentfiles/ perinatalGL.pdf. Accessed 1 May 2011.
30. Peytavin G, et al. 2007. Reduced lopinavir exposure during pregnancy: a case control study, abstr 579.Abstr. 14th Conf. Retroviruses Opportunistic Infect.
31. Peytavin G, et al. 2007. Genital tract diffusion of different HIV PI in HIV-1-infected pregnant women, abstr 744.Abstr. 14th Conf. Retroviruses Opportunistic Infect.
32. Read P, et al. 2010. Abstracts of the Second Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV. April 20-23, 2010. Manchester, United Kingdom. HIV Med. 11(Suppl. 1):1-119.
33. Roberts SS, et al. 2009. Lopinavir/ritonavir in pregnancy. J. Acquir. Immune Defic. Syndr. 51:456-461.
34. Sibiude J, et al. 2011. Large increase in prematurity between 1990 and 2009 in HIV-infected women in the National ANRS French Perinatal Cohort: does ritonavir boost play a role?, abstr 743.Abstr. 18th Conf. Retroviruses Opportunistic Infect.
35. Stek AM, et al. 2006. Reduced lopinavir exposure during pregnancy. AIDS 20:1931-1939. (Pubitemid 44427610)
36. Taylor G, Douglas M, Smith J. 2010. Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom. November 7-11, 2010. J. Int. AIDS Soc. 13(Suppl. 4):K13, O1-51, P1-237.
37. Thorne C, Patel D, Newell ML. 2004. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 18:2337-2339. (Pubitemid 39620231)
38. van der Lugt J, Colbers A, Burger D. 2008. Clinical pharmacology of HIV protease inhibitors in pregnancy. Curr. Opin. HIV AIDS 3:620-626.
39. Walter J, et al. 2006. Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts. J. Infect. Dis. 194:1510-1518. (Pubitemid 44851892)